Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Pharming het aandeel van 2017

50.750 Posts
Pagina: «« 1 ... 499 500 501 502 503 ... 2538 »» | Laatste | Omlaag ↓
  2. [verwijderd] 24 mei 2017 16:39

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Raadslid schreef op 24 mei 2017 16:35:

    Admin, krijgt diegene met de 10.000ste comment op dit draadje een bloemetje?
    Wat denk je wel dat bloemen kosten?
    Een heel aandeel van Pharming kan je krijgen.
    Mensen zijn ook nooit tevreden!
  7. forum rang 7 roon 24 mei 2017 17:13

    • roon

      Lid sinds: 30 dec 2014

      Laatste bezoek: 26 feb 2025

    • Aanbevelingen

      Ontvangen: 4215

      Gegeven: 2861

    •    Aantal posts: 6.957

    Sinds 14.00 uur zakt de koers geleidelijk.Heeft natuurlijk niets met de meeting te maken.
  13. forum rang 4 hangklok 24 mei 2017 17:28

    • hangklok

      Lid sinds: 26 okt 2012

      Laatste bezoek: 26 feb 2025

    • Aanbevelingen

      Ontvangen: 307

      Gegeven: 7

    •    Aantal posts: 4.796

    Elke dag deze week ging de koers in de laatste minuten omhoog. Nu zijn er wel erg weinig stukken verhandeld vandaag, dus ik verwacht het nu niet.
  17. forum rang 7 roon 24 mei 2017 18:18

    • roon

      Lid sinds: 30 dec 2014

      Laatste bezoek: 26 feb 2025

    • Aanbevelingen

      Ontvangen: 4215

      Gegeven: 2861

    •    Aantal posts: 6.957

    We zullen morgenvroeg wel wat analyses krijgen want zelfs van IEX zijn ze naar de AVA.

    Update 14:00 uur: Flow Traders en Pharming AVA's
    Vandaag hebben we niet één, maar twee AVA's in het IEXLiveblog. Collega Paul is naar Pharming en Roland Visser is aanwezig op de AVA van Flow Traders.

    Tja,hopelijk iets positiefs.
  19. [verwijderd] 24 mei 2017 19:21

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    dasherbusinessreview.com/is-pharming-...

    Fundamentele analyse van het verleden is leuk, maar voor een goede analyse van de huidige bedrijfswaarde moet je toch echt naar de toekomst kijken.
    Kijk eens naar de gemiddelde verwachte EPS/ROE/ROIC/ROA voor 2018/2019, dan komt er bij Pharming een heel andere conclusie uit dan kijken naar het verleden.

  20. forum rang 7 lucas D 24 mei 2017 20:28

    • lucas D

      Lid sinds: 27 jun 2007

      Laatste bezoek: 26 feb 2025

    • Aanbevelingen

      Ontvangen: 10626

      Gegeven: 8173

    •    Aantal posts: 30.903

    www.pharming.com/wp-content/uploads/2...

    1

    Pharming Reports On Annual General Meeting Of Shareholders

    Leiden, The Netherlands, 24 May 2017, Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.

    The presentation slides from today’s AGM are available on the Company’s website.

    The Board of Management

    Sijmen de Vries, CEO Bruno Giannetti, COO Robin Wright, CFO

    About Pharming Group N.V. Pharming is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Pharming’s lead product, RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (“HAE”) attacks in patients in Europe, the US, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
    RUCONEST® is commercialized by Pharming in Algeria, Andorra, Austria, Bahrain, Belgium, France, Germany, Ireland, Jordan, Kuwait, Lebanon, Luxembourg, Morocco, the Netherlands, Oman, Portugal, Qatar, Syria, Spain, Switzerland, Tunisia, the United Arab Emirates, the United Kingdom, the United States of America and Yemen.
    RUCONEST® is distributed by Swedish Orphan Biovitrum AB (publ) (SS: SOBI) in the other EU countries, and in Azerbaijan, Belarus, Georgia, Iceland, Kazakhstan, Liechtenstein, Norway, Russia, Serbia and Ukraine.
    RUCONEST® is distributed in Argentina, Colombia, Costa Rica, the Dominican Republic, Panama, and Venezuela by Cytobioteck, in South Korea by HyupJin Corporation and in Israel by Megapharm.
    RUCONEST® is also being investigated in a Phase II clinical trial for the treatment of HAE in young children (2-13 years of age) and evaluated for various additional follow-on indications.
    Pharming’s technology platform includes a unique, GMP-compliant, validated process for the production of pure recombinant human proteins that has proven capable of producing industrial quantities of high quality recombinant human proteins in a more economical and less immunogenetic way compared with current cell-line based methods. Leads for enzyme replacement therapy (“ERT”) for Pompé and Fabry’s diseases are being optimized at present, with additional programs not involving ERT also being explored at an early stage at present.
    Pharming has a long term partnership with the China State Institute of Pharmaceutical Industry (“CSIPI”), a Sinopharm company, for joint global development of new products, starting with recombinant human Factor VIII for the treatment of Haemophilia A. Pre-clinical development and


    2

    manufacturing will take place to global standards at CSIPI and are funded by CSIPI. Clinical development will be shared between the partners with each partner taking the costs for their territories under the partnership.
    Pharming has declared that the Netherlands is its “Home Member State” pursuant to the amended article 5:25a paragraph 2 of the Dutch Financial Supervision Act.
    Additional information is available on the Pharming website: www.pharming.com

    Forward-looking Statements

    This press release of Pharming Group N.V. and its subsidiaries (“Pharming”, the “Company” or the “Group”) may contain forward-looking statements including without limitation those regarding Pharming’s financial projections, market expectations, developments, partnerships, plans, strategies and capital expenditures.
    The Company cautions that such forward-looking statements may involve certain risks and uncertainties, and actual results may differ. Risks and uncertainties include without limitation the effect of competitive, political and economic factors, legal claims, the Company’s ability to protect intellectual property, fluctuations in exchange and interest rates, changes in taxation laws or rates, changes in legislation or accountancy practices and the Company’s ability to identify, develop and successfully commercialize new products, markets or technologies.
    As a result, the Company’s actual performance, position and financial results and statements may differ materially from the plans, goals and expectations set forth in such forward-looking statements. The Company assumes no obligation to update any forward-looking statements or information, which should be taken as of their respective dates of issue, unless required by laws or regulations.

    Contacts:

    Pharming Group N.V. Sijmen de Vries, CEO, Tel: +31 71 524 7400 Bruno Giannetti, COO, Tel: +31 71 524 7400

    FTI Consulting: Julia Phillips/ Victoria Foster Mitchell, Tel: +44 203 727 1136

    Lifespring Life Sciences Communication Leon Melens, Tel: +31 6 53 81 64 27
50.750 Posts
Pagina: «« 1 ... 499 500 501 502 503 ... 2538 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.019
AB InBev 2 5.506
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.705
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.714
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 189
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.752
Aedifica 3 916
Aegon 3.258 322.866
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.893
Agfa-Gevaert 14 2.050
Ahold 3.538 74.339
Air France - KLM 1.025 35.047
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.042
Alfen 16 24.886
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.273
AMG 971 133.495
AMS 3 73
Amsterdam Commodities 305 6.691
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.009
Apollo Alternative Assets 1 17
Apple 5 383
Arcadis 252 8.781
Arcelor Mittal 2.033 320.724
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.306
Aroundtown SA 1 219
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.192
ASML 1.766 107.585
ASR Nederland 21 4.498
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.675
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392

Macro & Bedrijfsagenda

  1. 27 februari

    1. Producentenvertrouwen februari (NL)
    2. Aalberts Q4-cijfers
    3. ArgenX Q4-cijfers
    4. AXA Q4-cijfers
    5. Beiersdorf Q4-cijfers
    6. Corbion Q4-cijfers
    7. Daimler Truck Q4-cijfers
    8. Telefónica Q4-cijfers
    9. Van Lanschot Kempen Q4-cijfers
    10. CTP Q4-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda